Our Foundation believes its mission is to promote the public healthcare sector and public healthcare in an international context.
There is a large degree of catch-up required in the diagnosis of leukemia, particularly in developing and newly industrialised countries. While there are already highly qualified and ambitious scientists active in these regions, the available infrastructure is unfortunately often still underdeveloped.
The starting situation can be improved by developing and modernising the equipment in molecular laboratories, and that improves the healthcare delivered on the ground. Doing this also contributes to global knowledge transfer, which in turn indirectly contributes more knowledge to the German healthcare sector.
In close consultation with scientists (Prof. Peter Valk, University of Rotterdam; and the leadership of the American Society of Hematology (ASH)) and hospitals on the ground, the Foundation has paid the costs for five countries and six laboratories in South America to procure the latest molecular analysis devices and consumable materials, along with their set-up and training. These facilities are in:
The devices were ordered beginning in November 2019 and have now been delivered. They will enter operation in the next few months following a short delay due to the coronavirus pandemic.
The Foundation is therefore fulfilling one of its core duties – achieving very high visibility while doing so – and is simultaneously available to advise local scientists together with the colleagues from Rotterdam. Further projects in this form are envisaged.